A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate except neuroendocrine carcinoma including small cell carcinoma
* Disease progressed on or after prior docetaxel-containing chemotherapy
* Prior 1 or 2 cytotoxic chemotherapy regimens for metastatic castration-resistant prostate cancer, at least 1 of which contains docetaxel
* Documented prostate cancer progression as documented by prostate specific antigen progression according to Prostate Specific Antigen Working Group criteria or radiographic progression in soft tissue or bone
* Surgically or medically castrated, with serum testosterone level \<50 ng/dL (1.7 nmol/L)
* Eastern Cooperative Oncology Group performance status score of \<=2
* Protocol-defined laboratory values
* Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

* Active infection or other medical condition that would make prednisone (corticosteroid) use contraindicated
* Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone twice daily
* Pathological finding consistent with neuroendocrine carcinoma of prostate including small cell carcinoma
* Uncontrolled hypertension (systolic BP \>=160 mmHg or diastolic BP \>=95 mmHg; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy)
* Active or symptomatic viral hepatitis or chronic liver disease, have a known infection with human immunodeficiency virus and/or hepatitis B virus or hepatitis C virus
* History of pituitary or adrenal dysfunction.
* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac ejection fraction measurement of \<50% at baseline
* Atrial fibrillation, or other cardiac arrhythmia requiring therapy
* Other malignancy within past 3 years (except basal or nonmetastatic squamous cell carcinoma of the skin)
* Known brain metastasis
* Prior therapy with abiraterone acetate or other CYP17 inhibitor(s), or investigational agent(s) targeting the androgen receptor for metastatic prostate cancer
* Prior therapy with ketoconazole for prostate cancer
* Surgery or local prostatic intervention within 30 days of the first dose
* Radiotherapy, chemotherapy, or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of Cycle 1 Day 1
* Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events grade of \<=1 (chemotherapy induced alopecia and grade 2 peripheral neuropathy is allowed)
* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Cycle 1 Day 1
* Anti-androgen treatment must not be given within 4 weeks (flutamide) or 6 weeks (bicalutamide or nilutamide) prior to Cycle 1 Day 1
* Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole) within 4 weeks prior to Cycle 1 Day 1
* Has known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients
* Has contraindications to the use of prednisone per local prescribing information
* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments